Exscientia is pleased to announce the formation of a neuroscience collaboration with Sunovion Inc.. The agreement focuses on ex scientia’s delivery of novel 'bispecific' compounds that combine activities at the GPCR and ion channel super families to treat psychiatric diseases. In terms of the agreement ex scientia receives full research funding. Further financial terms were not disclosed.
April 30, 2013
Exscientia signs proof-of-concept deal with Sunovion Inc. to discover 'bi-specific' compounts for psychiatric disease
Liked the article? Let’s share it!